SNY

Sanofi FR
NASDAQ

Real-time Quotes | Nasdaq Last Sale

51.51
+1.23
+2.45%
Opening 14:15 07/13 EDT
OPEN
51.20
PREV CLOSE
50.28
HIGH
51.72
LOW
51.13
VOLUME
472.66K
TURNOVER
--
52 WEEK HIGH
52.94
52 WEEK LOW
37.62
MARKET CAP
129.17B
P/E (TTM)
34.25
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SNY stock price target is 58.38 with a high estimate of 62.00 and a low estimate of 53.00.

EPS

SNY News

More
2 Healthcare IPOs Getting a Tailwind From COVID-19 to Consider Buying
MotleyFool.com · 1d ago
Britain to set out its position on EU vaccine scheme later on Friday
Reuters · 3d ago
Is It Too Late to Buy Novavax Stock?
MotleyFool.com · 3d ago
'Vaccine nationalism' could lead to the coronavirus devastating public health and the economy, experts warn
Analysts have predicted that a battle for access to an effective vaccine could stretch into 2021 or 2022.
CNBC.com · 3d ago
Sanofi to collaborate with Kymera Therapeutics in immune-inflammatory diseases
Sanofi (NASDAQ:SNY) inks an agreement with privately held Kymera Therapeutics aimed at developing and commercializing protein degrader therapies targeting
seekingalpha · 4d ago
Regeneron shares are up 2% after SunTrust upgrades the stock
Shares of Regeneron Pharmaceuticals Inc. were up 2.1% in trading on Thursday as SunTrust Robinson Humphrey analysts upgraded the stock to buy from hold, citing the strength of the company's drug pipeline. In a July 8 note to investors, they said that Regenero
MarketWatch · 4d ago
New $1 bln fund aims to steer antibiotic companies in tough market
Reuters · 4d ago
Kymera Therapeutics And Sanofi Enter Into Strategic Partnership To Advance Novel Protein Degrader Therapies To Patients
PR Newswire · 4d ago

Industry

Pharmaceuticals
+1.68%
Pharmaceuticals & Medical Research
+1.50%

Hot Stocks

Symbol
Price
%Change

About SNY

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.
More

Webull offers kinds of Sanofi SA (ADR) stock information, including NASDAQ:SNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SNY stock methods without spending real money on the virtual paper trading platform.